Clinicians

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Europe’s Preventable RSV Winter

Cardiometabolic care tracks glucose and blood pressure

HRR Testing Moves Upfront in Prostate Cancer

Cardiometabolic care is screening the pieces. It is not yet connecting them

FDA Redraws the TMB-High Treatment Line

A Self-Guided Pathway for Functional Seizures

Ebola’s Vaccine Trial Enters New Territory

Cardiac amyloidosis is no longer the whole story of protein misfolding

ESCAT v2 Makes Resistance Clinically Actionable
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
